<DOC>
	<DOCNO>NCT02600117</DOCNO>
	<brief_summary>Recent evidence suggest patient inactive chronic hepatitis B ( CHB ) may develop type liver complication patient active state hepatitis B virus ( HBV ) infection experience . Treatment guideline patient active state HBV infection indicate HBsAg clearance associate definitive remission activity chronic HBV &amp; improve long-term outcome . Clinical data show HBsAg clearance achievable , small population patient continuous treatment potent oral antiviral ( OAVs ) , tenofovir disoproxil fumarate ( TDF ) . It possible OAVs effect patient inactive CHB , short treatment duration . The purpose study find TDF effective control HBV DNA &amp; promote seroconversion HBsAg-positive HBsAb-positive patient inactive CHB .</brief_summary>
	<brief_title>Use TDF Patients With Inactive Chronic Hepatitis B Infection</brief_title>
	<detailed_description>Hepatitis B virus ( HBV ) infection major worldwide health problem . The course majority patient inactive chronic hepatitis B usually benign ; therefore , current treatment guideline recommend treat patient . However , recent evidence suggest prognosis inactive carrier exactly benign . For instance , patient may develop liver cancer despite inactive carrier state . Also , approximately 20-30 % patient inactive chronic hepatitis B may undergo spontaneous reactivation hepatitis time . Multiple episodes reactivation sustain reactivation cause progressive liver damage even liver decompensation . However , data support treatment oral antiviral alter outcome patient , remain untreated . Potent oral antiviral show suppress HBV DNA normalize liver enzyme patient active chronic hepatitis B infection . With continued long-term treatment , patient go clear hepatitis B surface antigen develop hepatitis B surface antibody . Therefore , possible oral antiviral effect patient inactive chronic hepatitis B , short duration treatment . This study explore possible use tenofovir disoproxil fumarate control HBV DNA promote hepatitis B surface antigen seroconversion patient inactive chronic hepatitis B . After completion initial investigation , patient start TDF 300mg daily . Patients review 6 monthly interval per standard care . At clinic visit , patient blood test include complete blood count , renal function , electrolytes , liver enzyme liver function test , well HBV serology include quantitative HBsAg HBV DNA . Patients also receive abdominal ultrasound , fibroscan fibrotest annual basis . Treatment stop sAg+ve seroconverts sAb+ve end 3 year whichever come early .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>All patient inactive chronic hepatitis B , define someone HBV DNA &lt; log4 , eAgve , eAb+ , HBsAg+ve normal ALT persistently &gt; 6 month Patients old 75 year age Presence hepatoma entry Presence decompensated cirrhosis define history variceal bleed , ascites , hepatic encephalopathy Presence abnormal renal function define serum creatinine &gt; 110Âµmol/L coinfection HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>